ACCELERATE2014 USER GROUP MEETING

Transcription

1 ACCELERATE2014 USER GROUP MEETING A MESSAGE FROM MAX The focus of this year s Accelerate2014 User Group Meeting was Delivering the Future of the Science-driven Enterprise. Supporting this overall theme, we had over 40 customer presentations and customer-driven sessions, many of them touching on the need for improved Scientific Product Lifecycle Management the new paradigm for quality, compliance and sustainability where chemistry, biology and materials meet. The many customer presentations demonstrated how science- and process-based organizations are improving operational efficiency by eliminating paper, how they are harmonizing procedures with the help of BIOVIA s common technology foundation, how they are improving product robustness with automated product and process monitoring. Customers spoke of how they are leveraging modeling to accelerate target analysis, improving quality with new material lifecycle management initiatives and building more cost-efficient and productive digital labs all with the help of integrated BIOVIA solutions. This document contains a complete list of customer talks presented at Accelerate2014 (pgs. I-III) along with summary details for a number of presentations from each industry track (pgs. 1-16). I invite you to join us at next year s user meeting, the BIOVIA Community Conference, to be held at the Orlando World Center Marriott, May 11-15, Best Regards, Max Carnecchia, CEO, Dassault Systèmes BIOVIA

2 ACCELERATE2014 USER GROUP MEETING CUSTOMER PRESENTATIONS Track 1: Process Management and Compliance Manufacturing Informatics Technology and Implementation Baxter Bioscience BIOVIA Discoverant Server Performance Monitoring Customer-Specific Applications in Product Development Johnson & Johnson BIOVIA Enterprise Lab Notebook Enables a Flexible Recipe-based Data Capture Strategy for Development Pfizer Meta Data and the Quest for Understanding: Utilizing BIOVIA Pipeline Pilot to Aggregate Notebook Content Customer-Specific Applications in QA/QC Amgen Integrating BIOVIA Products into Quality Control Labs Perrigo Where Are We Two Years Later? Post-deployment Review of the LES Integration of Labinformatics Solutions for QA/QC PPD Utilization of Inventory Manager in a CRO Environment Integration of BIOVIA and Third-party Solutions for Product Development Johnson & Johnson Support for Data Management and Automation Needs in Pharmaceutical Development Pfizer Faster, Easier and Ways to Prove It. Enhanced Experiments for Users, with Better Compliance and Data Mining for the ELN Administrator Manufacturing Informatics for Process Development BMS Product Robustness at Bristol-Myers Squibb BMS BIOVIA Discoverant as an Intelligence System for Pharmaceutical Development Previewing the Future of Manufacturing Informatics Biogen Idec Expanding the Usage of BIOVIA Discoverant into New Application Areas at biogen Idec: Driving Business Value in Supply Chain Operations and Commercialization of Biosimilars Track 2: Life Science Research Efficient Small Molecule Drug Design Pfizer Relative Free Energy Methods in Drug Discovery: Evaluation and Recommendations Vitae Pharma Contour Growth Algorithm Builds Novel Drug-like Molecules in the Context of Protein Binding Site Pipeline Pilot for Personal Productivity Dupont Improving the Effectiveness of Our R&D Organizations through Incrementally-enhanced Informatics Eisai With and Without the Magic: Leveraging Different Facets of Chemical Handling for Migration of BIOVIA ELN Data Informatics Solutions for Biologics and Biotherapeutics Discovery AbbVie Biologics Registration at AbbVie: Analysis and Future Approach Takeda Pharma Building a Highly Effective and Flexible Biomolecules Management Platform I

3 Discovery Cheminformatics Genentech, Inc. Merck Roche Deploying the BIOVIA Enterprise Lab Notebook at Genentech: Lessons Learned Enabling Library Design with BIOVIA Pipeline Pilot and ALDaS Serious Landscaping: Chemistry Platform Migration at Roche Accelerating Biotherapeutic Drugs to Market Pfizer Case Studies of the Contribution of Modeling in Drug Development: Target Analysis and Lead Humanization Putting the O back into Chemoinformatics BIOVIA Pipeline Pilot Merck Workbenches Play a Key Role in Developing and delivering Expert Analysis Track 3: Chemicals, CPG, Food & Beverage, Materials Laboratory and Experiment Management Colgate-Palmolive Digital Lab of the Future at Colgate Palmolive Gilead Using BIOVIA Pipeline Pilot to Extract BIOVIA Notebook Data Predictive Materials Science Air Products Computational Chemistry for Industrial Product and Process Development Support Dupont Thermochemical Design for Chemical and Materials Engineering Whirlpool Multi-scale Simulation of Cellulose Surface Detergency Process Chemical and Materials Management AkzoNobel How AkzoNobel Is Using BIOVIA CISPro Live to Address Corporate Requirements for Lab Safety and Chemical Inventory Management Dow Chemical Global Implementation of the CISPro Chemical Inventory System at the Dow Chemical company Procter & Gamble The Evolution of a Holistic Material Lifecycle Management Process Integrating the Scientific Laboratory Genentech Capturing Chemistry from Collaborators II

4 SELECTED CUSTOMER PRESENTATIONS Baxter Bioscience Pfizer Amgen Perrigo Bristol-Myers Squibb Biogen Idec Vitae Pharma AbbVie Takeda Pharma Genentech, Inc. Merck Colgate-Palmolive Whirlpool AkzoNobel Dow Chemical Procter & Gamble BIOVIA Discoverant Server Performance Monitoring...1 Meta Data and the Quest for Understanding: Utilizing...2 BIOVIA Pipeline Pilot to Aggregate Notebook Content Integrating BIOVIA Products into Quality...3 Control Labs Where Are We Two Years Later? Post-deployment...4 Review of the LES Product Robustness at Bristol-Myers Squibb...5 Expanding the Usage of BIOVIA Discoverant into New...6 Application Areas at Biogen Idec: Driving BusinessValue in Supply Chain Operations and Commercialization of Biosimilars Contour Growth Algorithm Builds Novel Drug-like Molecules...7 in the Context of Protein Binding Site Biologics Registration at AbbVie: Analysis and Future Approach...8 Building a Highly Effective and Flexible Biomolecules...9 Management Platform Deploying the BIOVIA Enterprise Lab Notebook at...10 Genentech: Lessons Learned Enabling Library Design with BIOVIA Pipeline Pilot and ALDaS...11 Digital Lab of the Future at Colgate Palmolive...12 Multi-scale Simulation of Cellulose Surface Detergency Process...13 How AkzoNobel Is Using BIOVIA CISPro Live to Address...14 Corporate Requirements for Lab Safety and Chemical Inventory Management Global Implementation of the BIOVIA CISPro Chemical Inventory...15 System at the Dow Chemical company The Evolution of a Holistic Material Lifecycle...16 Management Process III

5 BAXTER BIOSCIENCE DISCOVERANT SERVER PERFORMANCE MONITORING Steve Kane, Manager Information Systems, BioAnalytics Program, Baxter Bioscience Abstract: This presentation demonstrates how Baxter is using standard server performance data and a Discoverant hierarchy to monitor server and application performance. This capability allows Baxter to detect actual and potential performance issues, proactively plan server upgrades, identify bottlenecks and maintain service levels. Summary: Baxter s BioAnalytics Program is a global system initiative to provide access to all manufacturing data including process control systems, in-line device recordings, laboratory results, manufacturing execution data and other batch record data for eight worldwide sites. More than 10,000 parameters are mapped for process monitoring and/or investigational purposes with more than ten active BIOVIA Discoverant hierarchies and more than 500 active users. 1

6 PFIZER METADATA AND THE QUEST FOR UNDERSTANDING: UTILIZING BIOVIA PIPELINE PILOT TO AGGREGATE NOTEBOOK CONTENT Robert Wade, Research Fellow, Pfizer and Bryan Van Vliet, Director, Software Services, Consulting Services, BIOVIA Abstract: The initial push beyond the paper on glass paradigm for electronic notebooks requires at a minimum definitive metadata classification for each experiment entry. In the PharmaTherapeutics Division of R&D at Pfizer we have created such classifications that draw on authoritative sources. We have partnered with BIOVIA to leverage BIOVIA Pipeline Pilot and the Notebook IDS to create a powerful multi-dimensional experiment exploration and categorization tool. This presentation describes some of the methodology and highlights of the tool. Summary: Leveraging BIOVIA Pipeline Pilot to aggregate notebook content and metadata classifications for experiment entries, Pfizer has created a powerful, easy-to-use tool for drilling down into notebook data. The tool enables lab managers to quickly determine how compliant scientists are in their documentation, who is characterizing the new reference standard, what solvents were used throughout a project and other critical parameters. Ultimately, the tool is moving Pfizer from tactical, reactive, artifact-driven science to more strategic, information-driven science. 2

7 AMGEN INTEGRATING BIOVIA PRODUCTS INTO QUALITY CONTROL LABS Bruce Grieshaber, Director QC, Amgen; Sachin Sontakke, Senior Manager IS, Amgen Abstract: The presentation begins by explaining Amgen s implementation of BIOVIA Laboratory Execution System (LES) and BIOVIA Inventory Management (IM) including the benefits and lessons learned. The discussion continues with Amgen s enhancement plan for the architecture with a move from a site-based implementation to a regional model. Improvements in BIOVIA LES method building process with the use of parameters stored in BIOVIA IM are covered. The presentation concludes with some ideas for using BIOVIA Pipeline Pilot as a tool to integrate Amgen s quality and management systems. Summary: A BIOVIA LES and BIOVIA IM deployment strategy that that enables full proficiency within the lab requires a careful definition of the data model for storing specifications, in-process control limits, test results and test data. It is also important to ensure that electronic procedures align with reporting requirements. Carefully evaluate the resource skillset prior to assigning method building tasks. Define the instrument standards to reduce rework in parsing and registration and know up front if you are working towards a regional or site deployment of BIOVIA LES/IM software. 3

8 PERRIGO WHERE ARE WE TWO YEARS LATER? POST-DEPLOYMENT REVIEW OF THE BIOVIA LES Deb Baker, QC Informatics Supervisor, Perrigo; David Redding, QC Informatics Team Leader, Perrigo Abstract: Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier and is continually striving to fulfill the company s mission, To meet the world s growing need for quality, affordable healthcare. In order to support this vision, Perrigo has strategic goals that focus on both compliance and cost control. Perrigo Company is currently using the BIOVIA Laboratory Execution System (LES) and BIOVIA Inventory Management (IM) at our Allegan, Michigan site. We expect to Go Live by fall with the BIOVIA ELN in our AR&D lab in Michigan and BIOVIA LES at our New York site and we recently kicked off an BIOVIA LES implementation project at our Israel site. This presentation focuses on the benefits of our BIOVIA LES deployment two years after implementation at our Michigan site and the challenges we faced when implementing across multiple value streams and labs. Summary: Perrigo has observed numerous benefits resulting from the implementation of BIOVIA LES and BIOVIA IM over a period of 18 months. The software makes it easy to enforce consistency in testing and documentation practices, even across multiple laboratories. Ninety-six percent of analysts prefer BIOVIA LES to the previous paper system. Eight-eight percent report improved data recording. Written procedures have greatly reduced analyst errors, and compliance is improved with data and metadata now collected and recorded in real time. Most importantly, analysts spend more time testing now less time correcting errors. 4

9 BRISTOL-MYERS SQUIBB PRODUCT ROBUSTNESS AT BRISTOL-MYERS SQUIBB Gary Steeves, Manager, Biologics Process Robustness: GMS-IT, Bristol-Myers Squibb; Dan Wasser, Associate Director, Global Manufacturing and Supply IT, Bristol-Myers Squibb Abstract: Product Robustness within Bristol-Myers Squibb is a program that continually seeks to reduce variability in our manufacturing processes, products and supply with the ultimate goal of manufacturing sites with no investigations and no recalls. Global Manufacturing and Supply IT designs and deploys data systems and analytical tools to support this program. This talk shares Bristol-Myers Squibb s progress to date and covers the company s analytical goals, some of the technical solutions they have deployed (including Discoverant) and the challenges they have encountered. Summary: Product robustness is the ability of a process to demonstrate acceptable quality and performance while tolerating input variability. Process monitoring, process understanding and process verification constitute a strategic imperative at Bristol-Myers Squibb. BIOVIA Discoverant is a key component of their process and product robustness toolkit, automating process monitoring, providing trend alerts, supporting investigations and accelerating the preparation of annual product quality reviews (APQRs). Biologics hierarchies in BIOVIA Discoverant include 800-4,500 parameters that are monitored daily to reduce variability in processes, products and supply. 5

10 BIOGEN IDEC EXPANDING THE USAGE OF BIOVIA DISCOVERANT INTO NEW APPLICATION AREAS AT BIOGEN IDEC: DRIVING BUSINESS VALUE IN SUPPLY CHAIN OPERATIONS AND COMMERCIALIZATION OF BIOSIMILARS Yvonne Ledford, Data Acquisition and Analytics Program Lead, Biogen Idec Abstract: This presentation provides an overview of Biogen Idec s efforts to expand the usage of BIOVIA Discoverant and centralized data management into new application areas driving the business value across the supply chain, along with streamlining the commercialization process for biosimilars. The presentation focuses on the benefits, challenges and methodologies associated with leveraging Biogen Idec s data and process analytics excellence across business lines. Summary: Benefits of BIOVIA Discoverant for biosimilar manufacturing include ease of use and low-cost, rapid hierarchy roll-outs. With the hierarchy following the process flow, there is no need for lot tracking across steps. The system lays the groundwork for future hierarchy updates and removes the need for routine trending tools until a process moves to the validation phase. The ability to share data via limited access permissions makes it possible to give partners and CMOs limited hierarchy views. With BIOVIA Discoverant, pharma manufacturing organizations can expand systematic data acquisition, consistent data availability and sophisticated informatics across the supply chain. 6

11 VITAE PHARMACEUTICALS CONTOUR GROWTH ALGORITHM BUILDS NOVEL DRUG-LIKE MOLECULES IN THE CONTEXT OF PROTEIN BINDING SITE Suresh Singh, Senior Director, Vitae Pharma Abstract: Contour is a structure-based drug design technology that comprises a contextperceptive growth algorithm and a contact-sensitive scoring function. A flexible and programmable growth engine creates drug-like molecules by assembling fragments in the context of protein binding pockets. The context sensitive algorithm is designed to generate novel molecules that naturally complement hydrophilic and hydrophobic features of the protein binding site through its dynamic growth features. At each stage of the growth process the local binding site features are dynamically mapped, and these features pick high ranking fragments and attach them in the best direction(s) to grow. Once the fragments are assembled in the binding site, growth algorithm scans fragment atoms that are in contact with the protein atoms in the binding site and dynamically mutate select atoms into complementary hetero atoms. Thus these features generate molecules that best complement the shape and the features of protein binding sites. These improvements have significantly enhanced the growth rate up to 10 times over the previous version of the growth algorithm, and raised the average score of molecules generated by about 1 log unit. We demonstrate these features with application to renin, 11b-HSD1 and LXR. Summary: Contour technology was used to discover a new scaffold for inhibition of 11b-HSD1 and to guide optimization of potency and other properties. The software was used in virtual screening mode to discover a potent 11b-HSD1 inhibitor which was rapidly optimized to a singledigit nanomolar compound. The technology was instrumental in discovering clinical candidates for BACE1, LXRb agonists and RORginverse agonists. Contour technology is integrated into BIOVIA Discovery Studio for the front-end and BIOVIA Pipeline Pilot protocols for the back-end. 7

12 ABBVIE BIOLOGICS REGISTRATION AT ABBVIE: ANALYSIS AND FUTURE APPROACH Randy Metzger, Senior Informatics Scientist, Platform Informatics and Knowledge Management, AbbVie Abstract: AbbVie utilizes the BIOVIA Biological Registration (BioReg) System as its global enterprise software for registration of biologics materials throughout drug discovery. AbbVie was an original participant in the collaborative special interest group that helped to guide the creation of the initial release of BIOVIA BioReg. Since its early adoption, BIOVIA BioReg has become a central component for managing and integrating the information surrounding AbbVie s biologicsbased drug discovery efforts. Integration of BIOVIA BioReg has successfully enabled mapping of experimental data in multiple systems to the identifying information of biological entities, providing a wider breadth of knowledge management in the biologics space. Recently AbbVie has embarked on an in-depth analysis of its current biologics registration practices and philosophies, and has identified structural areas where the integrity of Concept information and relationships between Concepts may be improved. This talk describes reconfiguration of BIOVIA BioReg to implement a new model for managing information and relationships, and a new model of virtual Concept registration. Summary: The reconfiguration of BIOVIA BioReg has addressed AbbVie business needs by providing consistent Concept-level metadata among all lots and allowing for direct Concept relationships and virtual registration of Concepts. Simpler, state-based rules have improved stability, intuitiveness and the ability to test software. Simplified entity definitions allow greater flexibility in adding new entity subtypes and ability for post-registration editing of entity subtype classifications. The new user interface enables more accurate and consistent data entry workflows to meet Abbvie needs, including improved bulk registration. Data cleanup has enhanced data consistency and stability. 8

13 TAKEDA PHARMACEUTICALS BUILDING A HIGHLY EFFECTIVE AND FLEXIBLE BIOMOLECULES MANAGEMENT PLATFORM Monica Wang, Lead System Engineer, Project and Program Manager, R&D Systems, Takeda Pharmaceuticals Abstract: Building a comprehensive Biomolecules Management Platform is a very challenging task since there are many categories of biomolecular entities (e.g., cell lines, plasmids, proteins, antibody conjugates, etc.), each with vastly diverse properties and complicated relationships. We are building an enterprise solution to track individual biomolecules in different drug development workflows and visualize their relationships. This platform will improve user efficiency, data quality, data exchange and collaboration for both research and pre-clinical development departments across multiple R&D sites at Takeda. Summary: A pilot project assessing BIOVIA BioReg as a general-purpose system for registering biological assets and their relationships satisfied Takeda s requirements for single and batch biomolecule registration with easy entity configuration, entity relationship visualization, support for developing and optimizing antibody drug conjugates (ADCs), flexible searching and inventory tracking (made possible by a BIOVIA Pipeline Pilot application seamlessly integrated with BioReg). 9

14 GENENTECH DEPLOYING THE ACCELRYS (BIOVIA) ELN AT GENENTECH: LESSONS LEARNED Hao Zheng, Computational Chemist, Genentech, Inc. Abstract: Today Electronic Laboratory Notebooks (ELNs) play an important role in a scientist s workflow. They have become more than a replacement for the paper lab notebooks. They are an essential application for improving the efficiency of capturing and sharing information. Within medicinal chemistry, for example, the BIOVIA ELN can be integrated with other chemistry processes such as compound registration, analytical analysis and working with collaborators. This presentation discusses how the BIOVIA Notebook is deployed within the medicinal and process chemistry departments at Genentech. The presentation also describes several integrations Genentech has implemented to help chemists improve their workflows. Summary: In deploying the BIOVIA ELN within their medicinal, early lead, process and analytical chemistry groups, Genentech learned how important it is to identify must-have features early in the program. It is also critical to test performance and stability using large amounts of real data and pay close attention to the different priorities and workflows of chemists working in different areas. Use many pilot teams, chose the team members carefully and focus on their most frequently used tasks. Finally, since most documents are created using cloning, cloning a reaction needs to be an intuitive process. 10

15 MERCK ENABLING LIBRARY DESIGN WITH PIPELINE PILOT AND ALDaS Scott Harrison, Associate Principal Scientist, Cheminformatics, Merck Abstract: Chemists specializing in the design and synthesis of small molecule libraries typically have cheminformatics requirements above and beyond those doing traditional medicinal chemistry. Over the past 15 years, Merck has leaned on BIOVIA Pipeline Pilot as a means to quickly develop and deploy library workflow tools that have enabled library approaches within medicinal chemistry programs. The first part of this talk highlights the evolution of those tools from rudimentary protocols to increasingly complex design tools. The second part of the talk showcases the Automated Library Design and Synthesis (ALDaS) platform currently under development by BIOVIA in partnership with Merck. Summary: Library tools at Merck have evolved from entirely manual, spreadsheet-based solutions requiring expertise and experience to BIOVIA Pipeline Pilot-based tools simplifying file manipulation and editing that have lowered the barrier to entry for novice chemists. The migration of these tools to BIOVIA Pipeline Pilot webport has increased in-line help text support, eliminated file editing and further lowered the barrier for novice chemists. For example, enumeration in the Pipeline Pilot webport provides integration with QC, Purification and compound registration, while eliminating spreadsheet manipulation of data files. Custom BIOVIA Pipeline Pilot workflows for high-throughput purification use Oracle tables to track fractions in barcoded vials and racks, giving the chemist complete visibility into this process. A BIOVIA Experiment Knowledge Base (EKB) solution for high-throughput purification is currently being tested and deployed. 11

16 COLGATE-PALMOLIVE DIGITAL LAB OF THE FUTURE AT COLGATE-PALMOLIVE Robyn Mandalakis, Director PLM, Global Development, Colgate-Palmolive Abstract: This talk focuses on Colgate Palmolive s overall Product Lifecycle Management strategy and tools, and their digital laboratory vision, roadmap and progress to date. Summary: By carefully planning and aligning internally and with partners, Colgate-Palmolive is leveraging BIOVIA Electronic Lab Notebook (ELN), BIOVIA Work Request and BIOVIA Pipeline Pilot to provide quick and easy access to relevant people, knowledge and information in the Digital Lab. They started by getting to know their user groups. Now they are deploying flexible and agile ELNs for their R&D, microbiology and flavor/fragrance groups with a strong focus on tracking utilization, measuring success and celebrating success. They are also reducing busy work by importing equipment, materials and preparations used in one experiment into new experiments and by allowing scientists to clone sections or entire experiments into new experiments. It s all about getting information easily into the BIOVIA ELN. 12

17 WHIRLPOOL MULTI-SCALE SIMULATION OF CELLULOSE SURFACE DETERGENCY PROCESS Mir Quddus, Senior Engineer, Whirlpool Abstract: Textile surfaces are exposed to environmental and human contamination. These contaminants adhere onto the surface through physiochemical forces. Aqueous detergency process involves usage of water and detergents to remove these contaminants from the cellulose surface. Although much published literature exists pertaining to experimental studies on detergency process, only a few studies address multi-scale phenomena. This study focuses on the atomistic nature of cellulose surface soiling and the meso-scale approach to detergency. We use the commonly used cellulose surface as a substrate and oil to represent human contamination. Our results indicate that reduction of surface tension by the surfactant molecules occurs through selective adsorption on the cellulose surface and oil-cellulose interface. The detergency progressed with the reduction of van der Waals forces between oil molecules and cellulose. The surface tension values obtained from this simulation were correlated with experimental values. This study also finds interesting micelle shape transition due to increase in system temperature. Summary: Multi-scale simulation using BIOVIA Materials Studio helps Whirlpool decode the understanding of material properties at various levels. For example, Whirlpool researchers demonstrated that oil adhesion on a cellulose surface depends on surface roughness and accessibility of OH-groups. Oil film and oil droplet wetting on a cellulose surface increases with longer alkane chains. Increased bulk flow shearing speeds the removal of oil droplets from a cellulose surface and increased surfactant concentration promotes larger micelle formation. 13

18 AKZONOBEL HOW AKZONOBEL IS USING BIOVIA CISPRO TO ADDRESS CORPORATE REQUIREMENTS FOR LAB SAFETY AND CHEMICAL INVENTORY MANAGEMENT Jennifer Hergert, HSE Manager, Surface Chemistry RDI, AkzoNobel Abstract: AkzoNobel uses BIOVIA CISPro Cloud in several different labs at different sites throughout the United States. This presentation discusses the experience of one of those labs in implementing BIOVIA CISPro Cloud, how we are using the system and how it is addressing our corporate requirements for lab safety and chemical inventory management. Summary: AkzoNobel, a leading global supplier of specialty surfactants and polymers, implemented the BIOVIA CISPro Cloud chemical inventory management system at their Strongsville, Ohio R&D facility in 2012 and at Bridgewater, NJ in BIOVIA CISPro is meeting AkzoNobel s Laboratory Safety Standard by providing a complete, up-to-date substance register with appropriate substance hazard information (Safety Data Sheets) and support for annual inventory audits, container labeling, storage and disposal in accordance with regulatory requirements. BIOVIA CISPro is also being deployed at other R&D facilities across different AkzoNobel Business Units including a site at Brewster, NY (currently in process). 14

19 THE DOW CHEMICAL COMPANY GLOBAL IMPLEMENTATION OF THE BIOVIA CISPRO CHEMICAL INVENTORY SYSTEM AT THE DOW CHEMICAL COMPANY Matt Whaley, Associate Research Scientist, The Dow Chemical Company Abstract: In 2013, The Dow Chemical Company began a pilot of the CISPro chemical inventory system within a single building in Midland, MI. A year later, this system is being rolled out to sites across the globe with an emphasis on its use to improve safety, regulatory compliance and cost saving. This presentation describes the drivers for the implementation of a globally standardized inventory system, the challenges of using such a system across multiple geographies with different languages and regulatory issues and the workflow changes and efficiency improvements that have already been felt by researchers in the laboratory. Summary: Dow s safety culture is part of everything they do and every decision they make. They selected BIOVIA CISPro because it is an industry-standard chemical inventory system that offers definable user properties and strong generational tracking with no server cost. By offering a readily accessible, up-to-date inventory of commercial reagents, ready access to hazard information and improved handling of regulated materials, BIOVIA CISPro has reduced time spent on reporting so more time can be spent on ensuring practical, everyday lab safety. 15

20 PROCTER & GAMBLE THE EVOLUTION OF A HOLISTIC MATERIAL LIFECYCLE MANAGEMENT PROCESS Tom Lillie, Section Manager Procter & Gamble Digital Innovation Program, Procter & Gamble Abstract: Knowledge related to materials is the lifeblood of a product development organization. However, materials are often managed in various ways by multiple functions that do not take advantage of the synergies between their needs. Establishing a common core and work processes across all material types including chemicals, components, finished products, packaging, labels, supplies and equipment has been a key enabler for the overall innovation process. This presentation highlights the challenges and benefits of moving from diverse site- and functionspecific material management capabilities to a standard global process. Summary: Materials are the building blocks of P&G products. Since establishing an end-to-end Material Lifecycle Management (MLM) process for handling starting materials, chemicals and reagents, P&G has moved from 8 systems for managing material quality across 16 R&D technical centers in 8 countries (2005) to a single system managing all aspects of materials across 20 R&D centers in 9 countries (2014). With more than 90% of materials now in BIOVIA CISPro, they have improved data quality through greater visibility into supplier changes and more accurate inventory control. They are also operating more sustainably with fewer resources to manage and better training. All in all, operating costs have been reduced by more than $15 million per year. Our 3DEXPERIENCE Platform powers our brand applications, serving 12 industries, and provides a rich portfolio of industry solution experiences. Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 170,000 customers of all sizes in all industries in more than 140 countries. For more information, visit Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the Compass icon and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA and NETVIBES are commercial trademarks or registered trademarks of Dassault Systèmes or its subsidiaries in the U.S. and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval. 16 Dassault Systèmes Corporate Dassault Systèmes 175 Wyman Street Waltham, Massachusetts USA BIOVIA Corporate Americas BIOVIA 5005 Wateridge Vista Drive, San Diego, CA USA BIOVIA Corporate Europe BIOVIA 334 Cambridge Science Park, Cambridge CB4 0WN England WP